Taofeek K Owonikoko1, Mary W Redman2, Lauren A Byers3, Fred R Hirsch4, Philip C Mack5, Lawrence H Schwartz6, Jeffrey D Bradley7, Thomas E Stinchcombe8, Natasha B Leighl9, Tareq Al Baghdadi10, Primo Lara5, Jieling Miao2, Karen Kelly5, Suresh S Ramalingam11, Roy S Herbst12, Vassiliki Papadimitrakopoulou13, David R Gandara5. 1. Winship Cancer Institute, Emory University, Atlanta, GA. Electronic address: towonik@emory.edu. 2. SWOG Statistical Center, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA. 3. The University of Texas MD, Anderson Cancer Center, Houston, TX. 4. Mt Sinai Hospital, New York, NY. 5. UC Davis Comprehensive Cancer Center, Sacramento, CA. 6. Columbia University Medical Center, New York, NY. 7. Washington University School of Medicine in St Louis, St Louis, MO. 8. Duke Cancer Institute, Durham, NC. 9. Princess Margaret Cancer Centre, Toronto, Canada. 10. St Joseph Mercy Hospital/Michigan CRC NCORP, Ann Arbor, MI. 11. Winship Cancer Institute, Emory University, Atlanta, GA. 12. Yale University, New Haven, CT. 13. Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Abstract
PURPOSE: This signal finding study (S1400G) was designed to evaluate the efficacy of talazoparib in advanced stage squamous cell lung cancer harboring homologous recombination repair deficiency. PATIENTS AND METHODS: The full eligible population (FEP) had tumors with a deleterious mutation in any of the study-defined homologous recombination repair genes and without prior exposure to a PARP inhibitor. The primary analysis population (PAP) is a subset of FEP with alteration in ATM, ATR, BRCA1, BRCA2, or PALB2. Treatment consisted of talazoparib 1 mg daily continuously in 21-day cycles. A 2-stage design with exact 93% power and 1-sided 0.07 type I error required enrollment of 40 patients in the PAP in order to rule out an overall response rate (ORR) of 15% or less if the true ORR is ≥ 35%. RESULTS: The study enrolled 47 patients in the FEP, of whom 24 were in the PAP. The median age for the FEP was 66.7 years; 83% were male and 85% white. ORR in the PAP was 4% (95% confidence interval [CI], 0, 21) with disease control rate of 54% (95% CI, 33, 74). Median progression-free survival and overall survival were 2.4 months (95% CI, 1.5-2.8) and 5.2 months (95% CI, 4.0-10), respectively. In the FEP, ORR was 11% (95% CI, 3.6, 23), the disease control rate was 51% (95% CI, 36, 66), and the median duration of response was 1.8 months (95% CI, 1.3, 4.2). Median progression-free and overall survival were 2.5 months and 5.7 months, respectively. CONCLUSIONS: S1400G failed to show sufficient level of efficacy for single agent talazoparib in a biomarker defined subset of squamous lung cancer with homologous recombination repair deficiency.
PURPOSE: This signal finding study (S1400G) was designed to evaluate the efficacy of talazoparib in advanced stage squamous cell lung cancer harboring homologous recombination repair deficiency. PATIENTS AND METHODS: The full eligible population (FEP) had tumors with a deleterious mutation in any of the study-defined homologous recombination repair genes and without prior exposure to a PARP inhibitor. The primary analysis population (PAP) is a subset of FEP with alteration in ATM, ATR, BRCA1, BRCA2, or PALB2. Treatment consisted of talazoparib 1 mg daily continuously in 21-day cycles. A 2-stage design with exact 93% power and 1-sided 0.07 type I error required enrollment of 40 patients in the PAP in order to rule out an overall response rate (ORR) of 15% or less if the true ORR is ≥ 35%. RESULTS: The study enrolled 47 patients in the FEP, of whom 24 were in the PAP. The median age for the FEP was 66.7 years; 83% were male and 85% white. ORR in the PAP was 4% (95% confidence interval [CI], 0, 21) with disease control rate of 54% (95% CI, 33, 74). Median progression-free survival and overall survival were 2.4 months (95% CI, 1.5-2.8) and 5.2 months (95% CI, 4.0-10), respectively. In the FEP, ORR was 11% (95% CI, 3.6, 23), the disease control rate was 51% (95% CI, 36, 66), and the median duration of response was 1.8 months (95% CI, 1.3, 4.2). Median progression-free and overall survival were 2.5 months and 5.7 months, respectively. CONCLUSIONS: S1400G failed to show sufficient level of efficacy for single agent talazoparib in a biomarker defined subset of squamous lung cancer with homologous recombination repair deficiency.
Authors: Roy S Herbst; David R Gandara; Fred R Hirsch; Mary W Redman; Michael LeBlanc; Philip C Mack; Lawrence H Schwartz; Everett Vokes; Suresh S Ramalingam; Jeffrey D Bradley; Dana Sparks; Yang Zhou; Crystal Miwa; Vincent A Miller; Roman Yelensky; Yali Li; Jeff D Allen; Ellen V Sigal; David Wholley; Caroline C Sigman; Gideon M Blumenthal; Shakun Malik; Gary J Kelloff; Jeffrey S Abrams; Charles D Blanke; Vassiliki A Papadimitrakopoulou Journal: Clin Cancer Res Date: 2015-02-13 Impact factor: 12.531
Authors: Lauren Averett Byers; Jing Wang; Monique B Nilsson; Junya Fujimoto; Pierre Saintigny; John Yordy; Uma Giri; Michael Peyton; You Hong Fan; Lixia Diao; Fatemeh Masrorpour; Li Shen; Wenbin Liu; Boris Duchemann; Praveen Tumula; Vikas Bhardwaj; James Welsh; Stephanie Weber; Bonnie S Glisson; Neda Kalhor; Ignacio I Wistuba; Luc Girard; Scott M Lippman; Gordon B Mills; Kevin R Coombes; John N Weinstein; John D Minna; John V Heymach Journal: Cancer Discov Date: 2012-09-06 Impact factor: 39.397
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Talia Golan; Pascal Hammel; Michele Reni; Eric Van Cutsem; Teresa Macarulla; Michael J Hall; Joon-Oh Park; Daniel Hochhauser; Dirk Arnold; Do-Youn Oh; Anke Reinacher-Schick; Giampaolo Tortora; Hana Algül; Eileen M O'Reilly; David McGuinness; Karen Y Cui; Katia Schlienger; Gershon Y Locker; Hedy L Kindler Journal: N Engl J Med Date: 2019-06-02 Impact factor: 91.245
Authors: Nuala McCabe; Nicholas C Turner; Christopher J Lord; Katarzyna Kluzek; Aneta Bialkowska; Sally Swift; Sabrina Giavara; Mark J O'Connor; Andrew N Tutt; Małgorzata Z Zdzienicka; Graeme C M Smith; Alan Ashworth Journal: Cancer Res Date: 2006-08-15 Impact factor: 12.701
Authors: Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth Journal: Nature Date: 2005-04-14 Impact factor: 69.504